Investors Back Awakn’s Psychedelic Therapies, As Company Doubles Private Placement To $2M
Awakn Life Sciences Corp. (OTCQB:AWKNF), a company focused on the development of psychedelic therapeutics for addiction and mental health disorders, has announced an increase in the size of its ongoing private placement financing.
What Happened: Initially planned for $1 million, the offering has been expanded to $2 million, reflecting heightened investor interest and support. The company also confirmed the closing of the fourth tranche, securing an additional $394,286 through the sale of 857,143 units at $0.46 per unit, bringing the total funds raised …